 Rafael Andre Da Silva
Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Formyl Peptide | 2 | 2026 | 17 | 1.870 |
Why?
| | Eye Diseases | 2 | 2026 | 94 | 1.730 |
Why?
| | Oligopeptides | 2 | 2019 | 269 | 1.020 |
Why?
| | Receptors, Lipoxin | 1 | 2025 | 6 | 0.940 |
Why?
| | Anti-Inflammatory Agents | 2 | 2019 | 475 | 0.890 |
Why?
| | Candida albicans | 2 | 2020 | 61 | 0.770 |
Why?
| | beta-Alanine | 2 | 2018 | 23 | 0.680 |
Why?
| | Nystatin | 1 | 2020 | 3 | 0.650 |
Why?
| | Interferon Type I | 1 | 2021 | 145 | 0.630 |
Why?
| | Angiotensin I | 1 | 2019 | 7 | 0.590 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 47 | 0.550 |
Why?
| | Physical Endurance | 2 | 2024 | 278 | 0.550 |
Why?
| | Dietary Supplements | 3 | 2024 | 576 | 0.540 |
Why?
| | High-Intensity Interval Training | 1 | 2018 | 46 | 0.540 |
Why?
| | Aortic Diseases | 1 | 2019 | 124 | 0.520 |
Why?
| | Vascular Remodeling | 1 | 2019 | 205 | 0.500 |
Why?
| | Aorta, Thoracic | 1 | 2019 | 286 | 0.480 |
Why?
| | Dengue | 3 | 2026 | 89 | 0.470 |
Why?
| | Peptide Fragments | 1 | 2019 | 699 | 0.440 |
Why?
| | Inflammation | 1 | 2025 | 2880 | 0.410 |
Why?
| | Energy Metabolism | 1 | 2018 | 936 | 0.370 |
Why?
| | Lactic Acid | 3 | 2024 | 302 | 0.330 |
Why?
| | Macrophages | 1 | 2019 | 1511 | 0.330 |
Why?
| | Rare Diseases | 2 | 2021 | 113 | 0.320 |
Why?
| | Zika Virus Infection | 2 | 2026 | 168 | 0.310 |
Why?
| | Biomarkers | 1 | 2021 | 4275 | 0.300 |
Why?
| | Athletic Performance | 2 | 2024 | 76 | 0.300 |
Why?
| | Brazil | 6 | 2026 | 180 | 0.280 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2019 | 233 | 0.250 |
Why?
| | Signal Transduction | 3 | 2026 | 5233 | 0.240 |
Why?
| | Mosquito Control | 1 | 2026 | 29 | 0.240 |
Why?
| | Mosquito Vectors | 1 | 2026 | 28 | 0.240 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2025 | 37 | 0.230 |
Why?
| | Aedes | 1 | 2026 | 65 | 0.230 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2025 | 81 | 0.220 |
Why?
| | Isomaltose | 1 | 2024 | 1 | 0.210 |
Why?
| | Animals | 9 | 2026 | 38109 | 0.210 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2025 | 136 | 0.210 |
Why?
| | Trehalose | 1 | 2024 | 35 | 0.210 |
Why?
| | Anserine | 1 | 2023 | 1 | 0.200 |
Why?
| | Carnosine | 1 | 2023 | 1 | 0.200 |
Why?
| | Polysaccharides | 1 | 2024 | 87 | 0.200 |
Why?
| | Propolis | 1 | 2022 | 1 | 0.190 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2023 | 12 | 0.190 |
Why?
| | Bicycling | 1 | 2024 | 120 | 0.190 |
Why?
| | Molecular Targeted Therapy | 1 | 2026 | 434 | 0.190 |
Why?
| | Fibrosis | 3 | 2023 | 548 | 0.190 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2023 | 132 | 0.180 |
Why?
| | Hypercholesterolemia | 1 | 2023 | 93 | 0.180 |
Why?
| | Rheumatic Diseases | 1 | 2023 | 97 | 0.180 |
Why?
| | Zika Virus | 2 | 2026 | 132 | 0.170 |
Why?
| | Cross-Over Studies | 1 | 2024 | 601 | 0.170 |
Why?
| | Hydrolyzable Tannins | 1 | 2020 | 6 | 0.160 |
Why?
| | Cytokines | 2 | 2019 | 2065 | 0.160 |
Why?
| | Humans | 20 | 2026 | 144957 | 0.160 |
Why?
| | Heart Rate | 1 | 2024 | 855 | 0.150 |
Why?
| | Exome | 1 | 2020 | 227 | 0.150 |
Why?
| | Intellectual Disability | 1 | 2021 | 175 | 0.150 |
Why?
| | Antifungal Agents | 1 | 2020 | 149 | 0.150 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2019 | 25 | 0.150 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2019 | 56 | 0.150 |
Why?
| | Microbial Sensitivity Tests | 1 | 2020 | 371 | 0.140 |
Why?
| | Kidney Diseases | 1 | 2023 | 427 | 0.140 |
Why?
| | Renin-Angiotensin System | 1 | 2019 | 78 | 0.140 |
Why?
| | Vaccines, Inactivated | 3 | 2023 | 70 | 0.140 |
Why?
| | Subcutaneous Tissue | 1 | 2018 | 26 | 0.140 |
Why?
| | Equisetum | 1 | 2017 | 1 | 0.140 |
Why?
| | Exercise Test | 2 | 2018 | 634 | 0.140 |
Why?
| | Interleukin-4 | 1 | 2019 | 206 | 0.140 |
Why?
| | Denture Bases | 1 | 2017 | 2 | 0.140 |
Why?
| | Lythraceae | 1 | 2017 | 3 | 0.140 |
Why?
| | Adhesives | 1 | 2017 | 15 | 0.140 |
Why?
| | Antibody-Dependent Enhancement | 1 | 2017 | 2 | 0.140 |
Why?
| | Foreign-Body Reaction | 1 | 2018 | 36 | 0.130 |
Why?
| | Mammary Arteries | 1 | 2017 | 8 | 0.130 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2017 | 30 | 0.130 |
Why?
| | Saphenous Vein | 1 | 2017 | 37 | 0.130 |
Why?
| | Prostheses and Implants | 1 | 2018 | 141 | 0.130 |
Why?
| | Martial Arts | 1 | 2016 | 3 | 0.120 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1253 | 0.120 |
Why?
| | Inflammation Mediators | 1 | 2019 | 509 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 1 | 2019 | 623 | 0.110 |
Why?
| | Hydrogen Peroxide | 1 | 2017 | 336 | 0.110 |
Why?
| | Biofilms | 1 | 2017 | 278 | 0.110 |
Why?
| | Coronary Vessels | 1 | 2017 | 251 | 0.110 |
Why?
| | Anti-Infective Agents | 1 | 2017 | 242 | 0.110 |
Why?
| | Interferon-gamma | 1 | 2018 | 784 | 0.110 |
Why?
| | Immunoglobulin G | 3 | 2023 | 893 | 0.100 |
Why?
| | Blood Glucose | 1 | 2024 | 2330 | 0.100 |
Why?
| | Muscle Strength | 1 | 2016 | 330 | 0.100 |
Why?
| | Disease Progression | 1 | 2021 | 2852 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2925 | 0.100 |
Why?
| | Antibodies, Viral | 3 | 2022 | 672 | 0.090 |
Why?
| | Dengue Virus | 2 | 2026 | 58 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2023 | 4569 | 0.090 |
Why?
| | Male | 8 | 2024 | 72406 | 0.090 |
Why?
| | Cells, Cultured | 1 | 2019 | 4155 | 0.080 |
Why?
| | Sports Nutritional Physiological Phenomena | 2 | 2024 | 3 | 0.080 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 5997 | 0.080 |
Why?
| | Immunocompromised Host | 2 | 2022 | 201 | 0.080 |
Why?
| | Mice | 3 | 2025 | 18365 | 0.070 |
Why?
| | Cohort Studies | 4 | 2021 | 5965 | 0.070 |
Why?
| | Exercise | 3 | 2023 | 2201 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2024 | 2029 | 0.060 |
Why?
| | Performance-Enhancing Substances | 1 | 2024 | 11 | 0.050 |
Why?
| | Glycogen | 1 | 2024 | 54 | 0.050 |
Why?
| | Glycemic Index | 1 | 2024 | 26 | 0.050 |
Why?
| | Adult | 4 | 2024 | 40506 | 0.050 |
Why?
| | Dipeptides | 1 | 2023 | 57 | 0.050 |
Why?
| | Muscle, Skeletal | 2 | 2024 | 1796 | 0.050 |
Why?
| | Rolipram | 1 | 2023 | 4 | 0.050 |
Why?
| | Dietary Carbohydrates | 1 | 2024 | 151 | 0.050 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2023 | 15 | 0.050 |
Why?
| | Physical Exertion | 1 | 2024 | 207 | 0.050 |
Why?
| | Cyclopropanes | 1 | 2023 | 83 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2025 | 451 | 0.050 |
Why?
| | Aminopyridines | 1 | 2023 | 127 | 0.040 |
Why?
| | Middle Aged | 3 | 2019 | 35928 | 0.040 |
Why?
| | Benzamides | 1 | 2023 | 224 | 0.040 |
Why?
| | Antibody Formation | 1 | 2023 | 294 | 0.040 |
Why?
| | Plant Extracts | 1 | 2022 | 187 | 0.040 |
Why?
| | Hospitals | 1 | 2026 | 732 | 0.040 |
Why?
| | Consanguinity | 1 | 2020 | 49 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 685 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 683 | 0.040 |
Why?
| | Prospective Studies | 2 | 2023 | 7997 | 0.040 |
Why?
| | Cell Line | 1 | 2025 | 2882 | 0.040 |
Why?
| | Spatial Analysis | 1 | 2019 | 23 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 14126 | 0.040 |
Why?
| | Caenorhabditis elegans | 1 | 2022 | 337 | 0.040 |
Why?
| | Demography | 1 | 2019 | 288 | 0.030 |
Why?
| | Myocardium | 1 | 2023 | 939 | 0.030 |
Why?
| | Stomatitis, Denture | 1 | 2017 | 2 | 0.030 |
Why?
| | Dental Cements | 1 | 2017 | 20 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2018 | 162 | 0.030 |
Why?
| | Acrylic Resins | 1 | 2017 | 45 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2018 | 194 | 0.030 |
Why?
| | Viremia | 1 | 2017 | 158 | 0.030 |
Why?
| | Leukocytes | 1 | 2018 | 295 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 456 | 0.030 |
Why?
| | Acidosis | 1 | 2016 | 105 | 0.030 |
Why?
| | Viral Load | 1 | 2017 | 526 | 0.030 |
Why?
| | Coronary Artery Bypass | 1 | 2017 | 269 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1496 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1327 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1423 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2017 | 452 | 0.030 |
Why?
| | Adolescent | 3 | 2019 | 22453 | 0.030 |
Why?
| | RNA, Viral | 1 | 2017 | 688 | 0.020 |
Why?
| | Female | 4 | 2026 | 78376 | 0.020 |
Why?
| | Athletes | 1 | 2016 | 419 | 0.020 |
Why?
| | Lung | 1 | 2025 | 4109 | 0.020 |
Why?
| | Incidence | 1 | 2019 | 2883 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2017 | 897 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2832 | 0.020 |
Why?
| | Child | 2 | 2020 | 22657 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 2609 | 0.020 |
Why?
| | Aged | 2 | 2019 | 25947 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 7191 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5872 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 8279 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 10792 | 0.010 |
Why?
|
|
Da Silva's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|